Secukinumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2766 publications
Juvenile pityriasis rubra pilaris in an adolescent successfully treated with secukinumab.
Journal: Italian journal of dermatology and venereology
Published: June 23, 2026
Retraction: Exploring the therapeutic potential of IL-17A inhibition in myasthenia gravis: a retrospective study on secukinumab.
Journal: BMJ neurology open
Published: June 17, 2026
Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.
Journal: Immunotherapy
Published: June 15, 2026
Advances in the treatment of pediatric hidradenitis suppurativa: emerging therapies and future directions.
Journal: Current opinion in pediatrics
Published: June 15, 2026
Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.
Journal: The Journal of rheumatology
Published: June 15, 2026
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
Journal: The New England journal of medicine
Published: June 03, 2026
Efficacy, Safety, and Tolerability of Secukinumab in Psoriatic Arthritis: A Systematic Review and Meta-Analysis.
Journal: The Annals of pharmacotherapy
Published: May 14, 2026
IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.
Journal: Respiratory medicine
Published: May 07, 2026
Corrigendum to "Secukinumab attenuates neuroinflammation and neurobehavior defect via PKCβ/ERK/NF-κB pathway in a rat model of GMH" [Exp Neurol. 2023 Feb; 360:114276].
Journal: Experimental neurology
Published: May 02, 2026
Intralesional secukinumab for localized, recalcitrant hidradenitis suppurativa: a case series of rapid symptom relief.
Journal: The Journal of dermatological treatment
Published: April 27, 2026
Last Updated: 06/30/2026